|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.36 HKD | +1.67% |
|
-9.64% | +0.74% |
Business description: 3SBio Inc.
Number of employees: 6,268
Sales by Activity: 3SBio Inc.
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
Development, Production, Marketing and Sale of Biopharmaceutical Products | 5.59B | 6.38B | 6.86B | 7.82B | 9.11B |
Geographical breakdown of sales: 3SBio Inc.
| Fiscal Period: December | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) |
|---|---|---|---|---|---|
Mainland China | 5.42B | 6.24B | 6.65B | 7.6B | 8.85B |
Others | 167M | 141M | 209M | 217M | 257M |
Executive Committee: 3SBio Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Jing Lou
CEO | Chief Executive Officer | 63 | 31/12/2005 |
Xiang He
DFI | Director of Finance/CFO | - | 02/07/2023 |
Dong Mei Su
PRN | Corporate Officer/Principal | 56 | 26/11/2014 |
Siu Kuen Lai
SEC | Corporate Secretary | 50 | 26/11/2014 |
Dong Tao Luo
PRN | Corporate Officer/Principal | 50 | 29/02/2016 |
Composition of the Board of Directors: 3SBio Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Jing Lou
CHM | Chairman | 63 | 02/04/2012 |
Dong Mei Su
BRD | Director/Board Member | 56 | 10/06/2012 |
Tian Ruo Pu
BRD | Director/Board Member | 57 | 31/05/2015 |
Hoi Ti Yang
BRD | Director/Board Member | 56 | 28/06/2021 |
Joo Yeow Ng
BRD | Director/Board Member | 61 | 20/01/2022 |
Jiaoe Zhang
BRD | Director/Board Member | 63 | 24/06/2024 |
Holdings: 3SBio Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
| 498,883,645 | 80.88% | 4 253 M $ | |
SENSORION 1.35% | 4,055,150 | 1.35% | 2 M $ |
Company details: 3SBio Inc.
Group companies: 3SBio Inc.
| Name | Category and Sector |
|---|---|
Hongkong Sansheng Medical Ltd.
 Hongkong Sansheng Medical Ltd. Develops and commercializes oral disintegration tablet formulation of antipruritic drug | |
Hongkong Sansheng Medical Ltd.
Hongkong Sansheng Medical Ltd. Develops and commercializes oral disintegration tablet formulation of antipruritic drug |
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.67% | -9.64% | +281.22% | +174.94% | 7.67B | |
| -0.23% | +3.26% | +8.96% | +3.70% | 77.51B | |
| +1.35% | +80.20% | +80.20% | +80.20% | 56.2B | |
| +0.68% | +2.48% | -33.54% | -39.93% | 58.79B | |
| -0.46% | -2.97% | +40.21% | +234.59% | 57.8B | |
| -1.53% | +4.57% | +19.67% | -41.11% | 25.5B | |
| -2.85% | -3.30% | +41.61% | +23.04% | 20.63B | |
| -7.92% | +13.63% | +12.13% | -75.87% | 20.27B | |
| +2.83% | -5.96% | +162.38% | +94.20% | 18.11B | |
| -1.04% | +4.54% | +114.94% | +835.68% | 15.4B | |
| Average | -0.78% | +1.70% | +72.78% | +128.94% | 35.79B | |
| Weighted average by Cap. | -0.40% | +1.23% | +39.20% | +83.30% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1530 Stock
- Company 3SBio Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition